Finance

Lists
KZIA:NASDAQ
Kazia Therapeutics Ltd
US$ ९.४७
-१.३०%
(-०.१२) 1D
अक्टोबर १, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KZIA...
Open
US$ ९.५६
High
US$ ९.६८
Low
US$ ९.३७
Mkt. cap
१४.४३ करोड
Avg. vol.
३.४१ लाख
Volume
१.३२ लाख
52-wk high
US$ १७.४०
52-wk low
US$ ४.८६
EPS
-US$ ६.३१
Beta
२.५४
Shares outstanding
१.५२ करोड
No. of employees
६
Open
US$ ९.५६
High
US$ ९.६८
Low
US$ ९.३७
Mkt. cap
१४.४३ करोड
Avg. vol.
३.४१ लाख
Volume
१.३२ लाख
52-wk high
US$ १७.४०
52-wk low
US$ ४.८६
EPS
-US$ ६.३१
Beta
२.५४
Shares outstanding
१.५२ करोड
No. of employees
६
News stories
From web sources and news partners
www.marketscreener.com
www.marketscreener.com
·
२३ मिनेट पहिले
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
GlobeNewswire
·
५० मिनेट पहिले
Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
Yahoo Finance
Yahoo Finance
·
५० मिनेट पहिले
Nasdaq to Hold Third Quarter 2026 Investor Conference Call
About Kazia Therapeutics Ltd
CEO-
Employees६
Founded१९९४
Headquarters-
Sector-
Analyst ratings
Based on 4 analysts giving stock ratings to KZIA in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for KZIA in the last 3 months.
Highest
Current US$ ९.४७
US$ ४०.०० (+३२२.३९%)
Average
US$ २९.२५ (+२०८.८७%)
Lowest
US$ १८.०० (+९०.०७%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Lee CFA
H.C. Wainwright
Buy
Reiterated
US$ १८.००
+९०.१%
10/01/2026
Kambiz Yazdi
BTIG
Buy
Maintained
US$ ४०.००
+३२२.४%
09/22/2026
John Newman
Canaccord Genuity
Buy
Reiterated
US$ २९.००
+२०६.२%
09/01/2026
Unknown Analyst
Canaccord Genuity
Buy
Initiated
US$ २९.००
+२०६.२%
08/13/2026
Naz Rahman
Maxim Group
Buy
Reiterated
US$ ३०.००
+२१६.८%
07/15/2026
Chad Messer
Lake Street
Buy
Initiated
US$ ३२.००
+२३७.९%
06/11/2026
Yale Jen
Laidlaw
Buy
Initiated
US$ २५.००
+१६४%
04/15/2026
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in AUD
२०२५ मार्च
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
Revenue
९.०३ लाख
९.०३ लाख
४५.९६ हजार
४५.९६ हजार
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
१५.२२ लाख
१५.२२ लाख
२४.९६ लाख
२४.९६ लाख
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१८.०६ लाख
१८.०६ लाख
४२.७९ लाख
४२.७९ लाख
Operating expense
३३.२८ लाख
३३.२८ लाख
६७.७५ लाख
६७.७५ लाख
Total operating expenses
३३.२८ लाख
३३.२८ लाख
६७.७५ लाख
६७.७५ लाख
Operating income
-२४.२४ लाख
-२४.२४ लाख
-६७.२९ लाख
-६७.२९ लाख
Other non operating income
-२.३९ लाख
-२.३९ लाख
३.७२ लाख
३.७२ लाख
EBT including unusual items
-५९.२९ लाख
-५९.२९ लाख
-६२.७६ लाख
-६२.७६ लाख
EBT excluding unusual items
-२६.४२ लाख
-२६.४२ लाख
-६२.७६ लाख
-६२.७६ लाख
Income tax expense
-८.०५ लाख
-८.०५ लाख
-
-
Effective tax rate
१३.५८%
१३.५८%
-
-
Other operating expenses
-
-
-
-
Net income
-५१.२४ लाख
-५१.२४ लाख
-६२.७६ लाख
-६२.७६ लाख
Net profit margin
-५६७.२३%
-५६७.२३%
-१३,६५५.५९%
-१३,६५५.५९%
Earnings per share
-
-
-
-
Interest and investment income
२१.६७ हजार
२१.६७ हजार
८०.४६ हजार
८०.४६ हजार
Interest expense
-
-
-
-
Net interest expenses
२१.६७ हजार
२१.६७ हजार
८०.४६ हजार
८०.४६ हजार
Depreciation and amortization charges
-
-
-
-
EBITDA
-२१.१३ लाख
-२१.९१ लाख
-६४.९६ लाख
-६४.९६ लाख
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू